A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
PHASE1
This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokine...
Status
Recruiting
Location
The First Affiliated Hospital of Zhengzhou University
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
PHASE2
This phase II trial studies how well a dose adjusted regimen consisting of ...
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
PHASE2
In the present trial the chemotherapy- light treatment concept R-Pola-Glo w...